Skip to main content

Table 3 Major results from the EGFR-scores analyses of non-small cell lung cancer (n = 47).

From: Comparison of the epidermal growth factor receptor protein expression between primary non-small cell lung cancer and paired lymph node metastases: implications for targeted nuclide radiotherapy

EGFR-scores characteristics

Cases

%

Primary tumors with 2+ or 3+

25

(53.2)

Lymph node metastases with 2+ or 3+

28

(59.6)

Unchanged EGFR-scores in lymph node metastases vs. the primary tumor

31

(66.0)

Changed EGFR-scores in lymph node metastases vs. the primary tumor

16

(34.0)

Patients who had 0 or 1+ in primary tumors and changed to 2+ or 3+ in lymph node metastases

6

(12.8)

Patients who had 2+ or 3+ in primary tumors and changed to 0 or 1+ in lymph node metastases

3

(6.4)

Patients who had 0 in primary tumors and changed to 1+, 2+ or 3+ in lymph node metastases

3

(6.4)

Patients who had 1+, 2+ or 3+ in primary tumors and changed to 0 in lymph node metastases

2

(4.2)